US FDA Grants Approval For Zanidatamab Ziihera Bispecific Antibody For Biliary Tract Cancer [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
Delhi, Nov. 25, 2024 (GLOBE NEWSWIRE) -- In November 2024, Jazz Pharmaceuticals announced that the US FDA granted accelerated approval for zanidatamab, a bispecific antibody, for the treatment of biliary tract cancer (BTC). This milestone is significant, as zanidatamab, now marketed under the name Ziihera, becomes the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the US. Ziihera is specifically indicated for adult patients with unresectable or metastatic HER2-positive BTC who are treatment-naive. This approval underscores the growing importance of bispecific antibodies in cancer treatment and marks a major achievement in the development of innovative therapies for difficult-to-treat cancers like BTC. Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: Bispecific Antibodies Development Proprietary Platforms Insight: 30 Platforms Global Bispecific Antibodies Market Size Yearly
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR Newswire
- Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR Newswire
- Jazz to search for new chief as CEO plans retirement [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Announces CEO Succession Plan [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 11/6/24 - Beat
JAZZ
Sec Filings
- 1/2/25 - Form 144
- 12/16/24 - Form 8-K
- 12/9/24 - Form 4
- JAZZ's page on the SEC website